| scholarly article | Q13442814 |
| P2093 | author name string | Rong Gao | |
| Xiu-Gui Sheng | |||
| Yong-Sheng Gao | |||
| An-Cong Wang | |||
| Feng-Xia Wu | |||
| Nai-Fu Liu | |||
| Zhi-Fang Ma | |||
| Yue-Bing Ma | |||
| P2860 | cites work | Unresponsiveness of MyD88-deficient mice to endotoxin | Q78093558 |
| Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene | Q22299417 | ||
| Toll-like receptors | Q27860671 | ||
| Pathogen recognition and innate immunity | Q27861084 | ||
| A human homologue of the Drosophila Toll protein signals activation of adaptive immunity | Q28131769 | ||
| Mycobacterium tuberculosis lipoarabinomannan-mediated IRAK-M induction negatively regulates Toll-like receptor-dependent interleukin-12 p40 production in macrophages | Q28279932 | ||
| Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6 | Q28292248 | ||
| Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4 | Q28611075 | ||
| MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. | Q33302912 | ||
| Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study | Q33348987 | ||
| Regulation of death receptor-mediated apoptosis pathways | Q34117899 | ||
| Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia | Q34235776 | ||
| Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis | Q34285076 | ||
| ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance | Q34303629 | ||
| The activation of Akt/PKB signaling pathway and cell survival. | Q34405519 | ||
| Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine | Q34947284 | ||
| Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs | Q36085634 | ||
| Taxol binds to cellular microtubules | Q36206521 | ||
| Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 | ||
| Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy | Q36558024 | ||
| Toll-like receptors expressed in tumor cells: targets for therapy | Q37078915 | ||
| Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells | Q39886489 | ||
| Paclitaxel binding to human and murine MD-2. | Q39957984 | ||
| Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro | Q40047160 | ||
| TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance | Q40165390 | ||
| TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer | Q40296306 | ||
| Toll-like receptors on tumor cells facilitate evasion of immune surveillance | Q40409088 | ||
| Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. | Q40944786 | ||
| Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures | Q41716249 | ||
| The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol | Q43704400 | ||
| MyD88 is involved in the signalling pathway for Taxol-induced apoptosis and TNF-alpha expression in human myelomonocytic cells | Q44078286 | ||
| The induction of macrophage gene expression by LPS predominantly utilizes Myd88-independent signaling cascades | Q45059172 | ||
| Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-α | Q63446380 | ||
| Shared actions of endotoxin and taxol on TNF receptors and TNF release | Q68086156 | ||
| Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma | Q73147564 | ||
| P53 mutation does not affect prognosis in ovarian epithelial malignancies | Q73820445 | ||
| P433 | issue | 3 | |
| P921 | main subject | toll-like receptor | Q408004 |
| paclitaxel | Q423762 | ||
| ovarian carcinoma | Q18556145 | ||
| P304 | page(s) | 871-877 | |
| P577 | publication date | 2013-12-16 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma in vitro | |
| P478 | volume | 7 |
| Q64906922 | Chemotherapeutic Agent Paclitaxel Mediates Priming of NLRP3 Inflammasome Activation. |
| Q36609391 | Clinical and Emergent Biomarkers and Their Relationship to the Prognosis of Ovarian Cancer |
| Q52730051 | Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8. |
| Q41619770 | Expression and clinical significance of SATB1 and TLR4 in breast cancer |
| Q38737142 | Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation |
| Q36297703 | Induction of oxidative stress by Taxol® vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA. |
| Q41702685 | Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance |
| Q52595047 | MiR-216a exerts tumor-suppressing functions in renal cell carcinoma by targeting TLR4. |
| Q92823981 | NF-κB Signaling in Ovarian Cancer |
| Q64911672 | Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics. |
| Q90585092 | Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT/FoxO1 pathway |
| Q41897007 | Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. |
| Q34501667 | Pretreatment of lipopolysaccharide (LPS) ameliorates D-GalN/LPS induced acute liver failure through TLR4 signaling pathway. |
| Q53749471 | Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro. |
| Q35796070 | TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth |
| Q37396607 | The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins |
| Q64261468 | Toll-like receptor 2 and Toll-like receptor 4 exhibit distinct regulation of cancer cell stemness mediated by cell death-induced high-mobility group box 1 |
| Q37269094 | Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett's esophagus, dysplasia and adenocarcinoma |
Search more.